Sheheryar K. Kabraji, BCH

Sheheryar Kabraji practices at Roswell Park Cancer Institute in Los Angeles, California.

Sheheryar Kabraji's NPI, 1326369562, was assigned on June 22, 2010. Sheheryar Kabraji holds Massachusetts license 252601.

Sheheryar Kabraji's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Sheheryar Kabraji's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Sheheryar Kabraji is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Sheheryar Kabraji practices. Vendor and product names are available with a free account.

Hematology and oncology is Sheheryar Kabraji's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Sheheryar Kabraji is licensed in Massachusetts.

CMS data shows 67 Medicare services from Sheheryar Kabraji across 2 procedure codes in 2024, all of them office visits, for 44 Medicare patients. Medicare paid $5,909 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 44 Medicare patients who saw Sheheryar Kabraji in 2024. The largest group is 65 to 74, with 19 patients. 75% of them have cancer, and 61% have high blood pressure. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Sheheryar Kabraji's median patient age at 68, with 98% women.

In 2024, Sheheryar Kabraji wrote 140 Medicare Part D claims for 59 patients. 74% of them were for generic drugs. CMS names the drug for 79 of them, across 3 drugs with 11 or more claims each, at $414,107 in total drug cost. In 2023, CMS named 81 claims across 2 drugs.

Sheheryar Kabraji accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 20 papers to Sheheryar Kabraji, published from 2012 to 2025. 2022 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Brain Neoplasms and Receptor, ErbB-2. Sheheryar Kabraji has published most often in Clin Cancer Res. Sheheryar Kabraji's most frequent co-authors are Sridhar Ramaswamy, MD, Carey Kernodle Anders, MD and Sarah Lenoir Sammons, MD.

CMS Open Payments shows 4 general payments to Sheheryar Kabraji from 3 drug and device companies in 2025. Consulting fees make up the largest share, 99% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,240.